Efficacy of the apatinib and icotinib combination therapy in the treatment of icotinib-resistant advanced lung adenocarcinoma: A case study

摘要

A patient with advanced lung adenocarcinoma who was unable to tolerate chemotherapy was controlled after combined treatment with apatinib. This case provides a basis for the treatment of this disease using this method. Methods: The diagnosis of patients with lung adenocarcinomastage Ⅳ period, age, detection of EGFR mutations, line for treatment in September there progress, a large number of pleural effusions, the right lung neoplasm, cisplatin andinterleukin-2 pleural perfusion chemotherapy, line again. Assessment of the EGFR gene exon 20single did not identify a missense mutation (T790M not mutation). Patients with high collar, poor health, refused chemotherapy. Subsequently, we administered oral treatment of apatinib at250 mg/day. Conclusion: Apatinib combined with EGFR-TKI targeted therapy is effective forlung adenocarcinoma. Moreover, adverse reactions can be controlled.